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Abstract
Ribosomal large subunit protein RPL41 is a basic (positively charged) peptide consisting of only 25 amino acids. An
antisense-based functional screening revealed that the down-regulation of RPL41 led to an anchorage-independent
growth of NIH3T3 cells in soft agar plates. RPL41 depletion with gene-specific small interfering RNA also resulted in
malignant transformation of NIH3T3 cells including increased tumor growth in mice. RPL41 deletion was detected
in 59% of tumor cell lines by fluorescence in situ hybridization analyses and RPL41 down-regulation in 75% of
primary breast cancers by real-time quantitative reverse transcription–polymerase chain reaction. These studies sug-
gest a tumor suppression role for RPL41. By mass spectrometry, RPL41 was associated with several cytoskeleton
components including tubulin β, γ, and myosin IIA, which was confirmed by Western blot analysis on both cellular
lysis and individually in vitro–expressed proteins. RPL41 also bound directly to polymerized tubulins. Cells over-
expressing a GFP-RPL41 were resistant to nocodazole-induced microtubule depolymerization. A synthetic RPL41
induced cellular α-tubulin acetylation and G2/M cell cycle arrest. These results indicate a stabilizing role of RPL41 on
microtubule. Microtubule spindles are essential for chromosome segregation duringmitosis. Cells with RPL41 knock-
downshowed abnormal spindles, frequent failure of cytokinesis, and formation of polynuclear cells. In interphase cells,
RPL41-depleted cells had premature splitting of centrosome.Our results provide evidence that RPL41 is amicrotubule-
associated protein essential for functional spindles and for the integrity of centrosome and that the abnormal mitosis
and disrupted centrosome associated with the RPL41 down-regulation may be related to malignant transformation.
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Introduction
Ribosomal proteins are a major component of ribosomes where cel-
lular proteins are synthesized. To date, approximately 80 ribosomal
proteins have been identified. In addition to their key role in protein
synthesis, some ribosomal proteins are involved in extraribosomal
functions, such as DNA repair, apoptosis, transcription regulation,
and translation regulation [1–6]. For example, the ribosomal protein
RPL13a can exit the ribosome on interferon IFN-γ treatment, bind
to specific messenger RNA, and translationally silence their expres-
sion, suggesting that the ribosome could act as a depot for some re-
leasable regulators [2].
Several ribosomal proteins have been found to be downregulated
in tumors, which is inconsistent with increased protein synthesis in
tumor cells and suggests that these proteins are more important to
cell proliferation and/or transformation than to the translation ma-
chinery [7,8]. Inactivation mutation of RPS6 in Drosophila led to
overgrowth of the lymph glands, abnormal blood cell differentiation,
and melanotic tumor formation [9]. Mutations and deletions of
RPL9 and RPL26 are associated with tumor progression in mice
[10]. In a zebra fish tumor model, 11 of 12 lines of zebra fish with
increased cancer incidence harbored a heterozygous inactivation
mutation in different ribosomal protein genes [11]. Several human
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cancer syndromes are associated with defective ribosomal genes.
Dyskeratosis congenita is characterized by premature aging and in-
creased tumors. One of the genes mutated in dyskeratosis congenita
is DKC1, which encodes a component of small nucleolar ribonucleo-
protein particles and functions in ribosomal RNA processing [12].
Diamond-Blackfan anemia is a congenital disease characterized by
defective maturation of erythroid progenitors and an increased risk
for several types of tumors. Multiple ribosomal protein genes, includ-
ing RPS19, RPS24, RPS17, or RPL35A, are inactively mutated [13–
17]. Recently, partial loss-of-function of RPS14 was associated with a
subgroup of myelodysplastic syndrome with chromosome 5q deletion
[18]. These studies all point to the hypothesis that some ribosomal
proteins function as tumor suppressors, although the exact mecha-
nisms are unclear [19].
Ribosomal protein RPL41 is a small peptide of 3456 Da consist-
ing of 25 amino acids, 17 of which are basic arginines and lysines.
Posttranslational modifications, including N-terminal loss of methi-
onine, acetylation, internal methylation, or hydroxylation, have not
been found in mature RPL41 [20]. It is believed that RPL41 is not
only the smallest but also the most basic eukaryotic protein [21].
RPL41 is highly conserved in eukaryotes and is present in certain
archaea but not in eubacteria [22]. In our attempt to identify cellular
transforming genes, we found that RPL41, when expressed in anti-
sense orientation, induced NIH3T3 cell transformation. The RPL41
down-regulation and deletions were frequently detected in human
tumors. These studies suggest a tumor suppression role for RPL41.
Further studies showed that RPL41 interacted with cytoskeleton
components, including tubulin β, γ, and myosin IIA, and a dynamic
cellular localization of RPL41 was found in mitotic cells. When RPL41
was downregulated, cells had abnormal mitosis and premature cen-
trosome split-apart. Our studies suggest that RPL41 is yet another ri-
bosomal protein whose deregulation is associated with tumors and that
the abnormal mitosis and defective centrosome integrity in cells with
RPL41 down-regulation may be related to malignant transformation.
Materials and Methods
Functional Screening for Transforming Genes
NIH3T3 cells and tumor cell lines were obtained from American
Type Culture Collection (ATCC, Manassas, VA) and cultured accord-
ing to the ATCC protocol. A functional screening for transforming
genes was performed by expressing complementary DNA (cDNA)
from a pool of primary tumors including four breast cancers and three
prostate cancers in NIH3T3 cells. Transfected cells were cultured
in 0.35% Bactoagar in RPMI 1640 with 10% fetal calf serum, and
transformed NIH3T3 cells were identified by their capability for
anchorage-independent growth [23].
Stable Cell Lines with RPL41 Knockdown
Two pairs of mouse RPL41-specific small interfering RNA (siRNA)
templates (pair no. 1, 5′-gatccgtggcggaagaagagaatgttcaagagacattctcttctt-
ccgccactta-3′ and 5′-agcttaagtggcggaagaagagaatgtctcttgaacattctcttcttcc-
gccacg-3′; and pair no. 2, 5′-gatccagatgaggcagaggtccaattcaagagattgga-
cctctgcctcatcttta-3′ and 5′-agcttaaagatgaggcagaggtccaatctcttgaattggac-
ctctgcctcatctg-3′) were synthesized (Invitrogen, Carlsbad, CA), annealed,
and ligated into pSilencer4.1-CMV neo vector (Ambion, Austin, TX)
according to the manufacturer’s protocol. Constructs were sequenced to
exclude mutations and transfected into NIH3T3 cells using Lipo-
fectamine 2000 (Invitrogen). Cells were selected in G418 (400 μg/ml)
for 2 weeks and subjected to Western blot analysis with antibody specific
to RPL41. Both cell lines, which resulted in approximately 50% (RPL41
siRNA no. 1) and 80% (RPL41 siRNA no. 2) decreases in RPL41, were
used for the evaluation of transforming capacities by soft agar assays. Cell
line RPL41 siRNA no. 2 was used for the studies of abnormal mitosis and
premature centrosome split.
Fluorescence In Situ Hybridization
RPL41 BAC clone CTD-2560J16 was purchased from CHORI
(Oakland, CA). DNA from BAC clone was isolated, biotin-labeled
with a BioprimeDNA Labeling kit (Invitrogen), and purified over a fine
Sephadex column. For chromosome preparation, cells were treated with
colcemid and hypotonic solution, and fixed in methanol/acetic acid
fixative. Chromosome spreads were dropped on glass slides. For hybridi-
zation, an RPL41 probe and a chromosome 12 centromere-specific
probe (Abbott, Abbott Park, IL) were mixed, added to slides, sealed,
and denatured at 80°C for 2 minutes. Hybridization was performed
in a humidified oven overnight. After washing, probes were detected
with fluorochrome-conjugated antibodies and analyzed under a fluores-
cence microscope.
Quantitative Real-time Reverse Transcription–Polymerase
Chain Reaction for RPL41 Expression
Total RNA was isolated from frozen tumors and matched normal
specimens and was reverse-transcribed with iScript reverse transcriptase
(Bio-Rad, Hercules, CA). RPL41 transcript was amplified in the pres-
ence of SYBRGreen on a Bio-Rad iCycler with RPL41-specific primers
(F/RPL41: 5′-gccgtagacggaacttcgcc-3′; and R/RPL41: 5′-tctgctcctgtgg-
cctccac-3′). β-Actin ACTB was also amplified as the reference gene (F/
ACTB: 5′-ttctacaatgagctgcgtgtg-3′; and R/ACTB: 5′-ggggtgttgaaggtct-
caaa-3′). Quantitation of RPL41 expression was performed using the
standard curve method. Polymerase chain reactions (PCRs) were
performed by initial denaturation at 95°C for 1 minute followed by
35 cycles of denaturation at 94°C for 30 seconds, annealing at 60°C
for 30 seconds, and extension at 72°C for 30 seconds.
Glutathione S-Transferase Pull-down Experiments
Human RPL41 was amplified by reverse transcription (RT)–PCR
(F/RPL41 cDNA: 5′-cctttctctcggccttagcgcc-3′, and R/RPL41 cDNA:
5′-cttcagctaaaacagcggaagaggtg-3′). First RPL41 PCRproduct was ream-
plified by a pair of nested primers (F/RPL41/glutathione S -transferase
[GST] BamH1: 5′-atccacggatccatgagagagccaagtggaggaag-3′, and R/
RPL41/GST EcoRI: 5′-gaattgaattcccagcgtctggcattccatg-3′), digested
with BamH1 and EcoRI, and inserted into pGEX-4T-3 (GE Health-
care Life Sciences, Waukesha, WI). Both PCRs were performed by
initial denaturation at 95°C for 1 minute followed by 30 cycles of de-
naturation at 94°C for 30 seconds, annealing at 60°C for 30 seconds,
and extension at 72°C for 30 seconds. For the GST/scrambled RPL41
construct that expresses a GST-scrambled RPL41 with all basic amino
acids of RPL41 moved to the C-terminal end (NH2-QSMAWLMM-
RRRRRRRRRRKKKKKKK-OH), two 86-bp oligos containing a
BamH1 site at 5′-end and an EcoRI site at 3′-end (F/ScramL41GST:
5′-gatcccaatctatggcttggctcatgatgcgtcgccgacggagaaggcgccgaagaaggaaaaa-
gaaaaagaaaaagaaatgaccg-3′, and R/ScramL41GST: 5′-aattcggtcatttc-
tttttctttttctttttccttcttcggcgccttctccgtcggcgacgcatcatgagccaagccatagattgg-3′)
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were annealed and inserted into pGEX-4T-3. For theGST/arginine–rich
peptide construct that expresses a GST-arginine–rich peptide with all
the nonarginine amino acids in RPL41 replaced by glutamic acid
(NH2-EREEEREERERREERERREEREREE-OH), two 86-bp oligos
containing a BamH1 site at 5′-end and an EcoRI site at 3′-end (F/
ArgrichGST: 5′-gatccgaacgtgaagaagaacgtgaagaacgtgaacgtcgtgaag-
aacgtgaacgtcgtgaagaacgtgaacgtgaagaatgaccg-3′, and R/ArgrichGST:
5′-aattcggtcattcttcacgttcacgttcttcacgacgttcacgttcttcacgacgttcacgttctt-
cacgttcttcttcacgttcg-3′) were annealed and inserted into pGEX-4T-3.
GST constructs were expressed in Escherichia coli BL21 cells. Recombi-
nant proteins were purified according to a standard protocol. Pull-down
assays were performed by preincubatingGSTproteins with 0.1%bovine
serum albumin in NTEN buffer (0.5% NP40, 1 mM EDTA, 20 mM
Tris, pH 7.4, and 200 mM NaCl) for 5 minutes at room temperature.
To identify the RPL41-interacting proteins by microcapillary liquid
chromatography–tandem mass spectrometry (LC/MS/MS), cell lysates
from 1 × 107 cultured cells were precleaned by incubation with 50 μl of
glutathione-agarose beads and incubated with 10 μg of GST protein
(control) or 10 μg of GST-RPL41 for 2 hours at 4°C with end-over-
endmixing. Beads were washed six times with NTEN. Binding proteins
were eluted, separated in SDS-PAGE, and analyzed by microcapillary
LC/MS/MS. For in vitro expression of tubulin α, β, and γ, and myosin
IIA (two overlapping fragments), RT-PCR was performed on human
cDNA using gene-specific primers (F/TUBA: 5′-agttctcactgagacctgt-
cacc-3′, and R/TUBA: 5′-taaccgtgcaaggaaactgtttatttcg-3′; F/TUBB:
5′-ggcgcattccaaccttccagcctgcg-3′, and R/TUBB: 5′-ctactatgtgccaggcact-
gttctag-3′; F/TUBG: 5′-ctggcgtgcggcgccgttgcgggcg-3′, and R/TUBG:
5′-cagtcaggcagggcttgggccaaccag-3′; F/MYH9: 5′-atccaggttcaggtcctggcta-
taagtcac-3′, and R/MYH9: 5′-gggaggctgtggtgtctgtctgtccatc-3′). PCR
products were subjected to reamplification (nested PCR) with gene-
specific primers with T7 promoter sequence incorporated (F/TUBA/ATG
T7: 5′-ggatcctaatacgactcactataggaacagaccaccatgcgtgaatgcatctcagtcca-3′, and
R/TUBA/nest: 5′-aacatagtgaataggctccaggcag-3′; F/TUBB/ATG T7: 5′-
ggatcctaatacgactcactataggaacagaccaccatgagggaaatcgtgcacatcca-3′, and
R/TUBB/nest: 5′-ggcagttgagtaagacggctaagg-3′; F/TUBG/ATG T7: 5′-
ggatcctaatacgactcactataggaacagaccaccatgccgagggaaatcatcaccctac-3′, and
R/TUBG for half nested; F/MYH9NTT7: 5′-ggatcctaatacgactcactatag-
gaacagaccaccatggcacagcaagctgccgataagtat-3′, and R/MYH9 NEST: 5′-
catctcaggctgcaggagaagag-3′; F/MYH9 CT T7: 5′-ggatcctaatacgactcact-
ataggaacagaccaccatggtcaagccgctgctgcaggtg-3′, and R/MYH9 for half
nested). PCR products were visualized in 0.8% agarose gel and used
directly for in vitro TNT analysis using the TNT Quick Coupled
Transcription/Translation System (Promega, Madison, WI) according
to the manufacturer’s instructions. TNT products were mixed with 1 μg
each of GSTor GST-RPL41 beads. The reaction was incubated for 1 hour
at 4°C. Beads were washed six times with NTEN. Binding proteins were
eluted, separated in 4% to 12% polyacrylamide gel, fixed, visualized by
incubating with fluorography Amplify solution (Amersham, Piscataway,
NJ), and exposed to X-ray films overnight at room temperature. Note that
GST-RPL41 was typically contaminated with heavy DNA/RNA and
that GST-RPL41was pretreated withDNase 4U (Ambion) and RNase
100 μg/ml in 150 μl of reaction buffer at 37°C for 30 minutes.
RPL41 Peptide and Anti-RPL41 Antibody
The RPL41 peptide (NH2-MRAKWRKKRMRRLKRKRRKM-
RQRSK-OH) was synthesized at Biosyn, Inc. The peptide was HPLC
purified to more than 95% and analyzed by mass analysis and analyt-
ical HPLC. For generating anti-RPL41 antibody, a full-length RPL41
with the addition of a cysteine and a glycine at N-terminal was used as
antigen. The cysteine residue was added for optimal conjugation of the
peptide with carrier protein keyhole lympet hemocyanin. The glycine
was added to block the amino group on cysteine. Two New Zealand
rabbits were immunized with five boosts. Crude serum was collected
at 6th, 8th, and 10th weeks and purified over a Melon Gel IgG Pu-
rification column (Thermo, Rockford, IL).
RPL41 Immunofluorescence Staining
Human fibroblasts were cultured in chamber slides (Lab-Tek,
Scotts Valley, CA), rinsed in PBS, fixed in 4% paraformaldehyde in
PBS for 15 minutes, washed twice in PBS, incubated with 1.5% Triton
X-100 for 5 minutes, washed twice in PBS, blocked in 10% goat serum
in PBS solution for 2 hours, incubated with 5 μl of anti-RPL41 rabbit
antibody and 2 μl of anti-B23 mouse antibody (clone FC82291;
Sigma, St. Louis, MO) in 500 μl of 2% goat serum for 1 hour or over-
night at 4°C, washed two times in PBS, incubated with 1 μl of fluores-
cein isothiocyanate (FITC)–conjugated goat antirabbit antibody (Santa
Cruz Biotech, Santa Cruz, CA) and 1 μl of rhodamine-conjugated goat
antimouse antibody (Invitrogen) in 500 μl of 2% goat serum for 1 hour,
washed three times in PBS, and counterstained with 4′,6-diamidino-
2-phenylindole. Immunofluorescence staining with α- and γ-tubulin
was similar to the procedure described previously except that cells were
fixed in −10°C methanol for 5 minutes.
Microtubule Cosedimentation
Purified tubulin (Cytoskeleton, Denver, CO) was dissolved in PEM
buffer (100 mM PIPES, pH 6.8, 1 mM EGTA, and 1 mM MgCl2) at
a final concentration of 500 ng/ml. Synthetic RPL41 peptide dissolved in
distilled water and tubulin solution were centrifuged for 30 minutes at
14,000 rpm in 4°C to remove any aggregates. GTP (1mM) and paclitaxel
(20 μM) were added to the tubulin solution, and the solution was incu-
bated at 37°C for 30 minutes for polymerization. RPL41 peptide (10 μg)
was mixed with polymerized tubulin (50 μg) and incubated for 10 min-
utes at 37°C. Samples were layered onto a 10% sucrose cushion contain-
ing 20 μM of paclitaxel and centrifuged for 20 minutes at 14,000 rpm
in a tabletop centrifuge. Supernatants and sediments were analyzed by
SDS-PAGE and Coomassie brilliant blue staining.
Results
Down-regulation of RPL41 Induces Cell Transformation
A functional screening for transforming genes was performed by
expressing cDNA from primary tumors in nonneoplastic NIH3T3
cells. Transfected cells were cultured in soft agar plates, and trans-
formed NIH3T3 cells were identified by their capability for anchorage-
independent growth. The transforming genes were recovered by cDNA
adaptor PCR and sequenced. Genes expressed in sense orientation were
considered candidate oncogenes, and those expressed in antisense ori-
entation, which could potentially downregulate the expression of their
counterpart in cells, were considered candidate tumor suppressor genes
[23]. One of the genes identified was RPL41, which was expressed in
antisense orientation. The expression of antisense RPL41 resulted in an
approximately 80% decrease of cellular RPL41 in NIH3T3 cells by
Western blot analysis with a custom antibody specific to RPL41 (see
Online Supplemental Material for specificity evaluation of anti-RPL41
antibody; Figure W1). To further confirm that the down-regulation
of RPL41 causes cell transformation, we cloned two mouse RPL41-
specific siRNA oligos into pSilencer 4.1-CMV vector and stably ex-
pressed them in NIH3T3 cells, which resulted in approximately 50%
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(RPL41 siRNAno. 1) and80% (RPL41 siRNAno. 2) decreases inRPL41,
respectively (Figure 1A). Multiple foci were formed in cells expressing
both RPL41 siRNA but not in control cells (Figure 1B). Soft agar assays
showed a significant increase in anchorage-independent colonies in cells
expressing both RPL41 siRNA compared with control cells (Figure 1,C
andD). Tumorigenesis of NIH3T3 expressing RPL41 siRNA no. 2 was
studied in athymic CD-1 nude mice by injecting 2 × 107 cells subcuta-
neously on both sides of the flanks. After 4 weeks, seven of eight sites
injected with RPL41-depleted cells developed palpable tumors, whereas
none of the eight sites injected with control cells developed tumors.
Deletion and Down-regulation of RPL41 in Human Tumors
To evaluate potential RPL41 mutation in human tumors, we per-
formed PCR to amplify a 914-bp genomic region covering the en-
tire RPL41 coding sequence. No mutations or homozygous deletions
of RPL41 were identified in 22 tumor cell lines (ATCC; Table W1).
Fluorescence in situ hybridization (FISH) analysis with a BAC clone
containing RPL41 (CTD-2560J16; CHORI) and a chromosome
12 centromere control probe (Vysis, Inc) showed RPL41 allelic re-
duction in 13 of 22 tumor cell lines (Figure 2A; Table W1). Real-time
quantitative RT-PCR was performed on 12 primary breast cancers
and their matched normal tissues in the presence of SYBR Green.
Of 12 breast cancers, 9 showed significant RPL41 down-regulation
(Figure 2B; Table W2). Interestingly, one case (case no. 9) showed
barely detectable RPL41 in both tumor specimen and normal tis-
sue, and a constitutional RPL41 inactivation could not be excluded.
Similar RPL41 down-regulation was also revealed by a search of the
ONCOMINE GeneChip array database in a large variety of tumors,
including breast cancer, lung cancer, head and neck squamous cell car-
cinoma, malignant glioblastoma, ovarian cancer, glioma, bladder tran-
sitional cell carcinoma, melanoma, and adenoid cystic carcinoma of
the salivary gland [24].
RPL41 Is a Microtubule-Associated Protein
To identify proteins that interact with RPL41, RPL41 was expressed
in E. coli as a fusion to GST, purified by use of glutathione agarose
beads, and incubated with human cell lysate. Proteins associated with
GST-RPL41 were separated in SDS-PAGE and identified by micro-
capillary LC/MS/MS. Cytoskeleton components, including tubulin
α, β, and γ, and myosin IIA, were found to associate with GST-
RPL41. Western blot analysis showed that these cytoskeleton com-
ponents were all effectively pulled down by GST-RPL41 but not by
several controls, including a GST, a GST-scrambled RPL41, or a GST
arginine-rich peptide (Figure 3A). The interaction between the endog-
enous RPL41 and cytoskeleton components was confirmed by a coim-
munoprecipitation assay; Cellular RPL41 complex pulled down by the
anti-RPL41 antibody contained tubulin α, β, and γ, and myosin IIA
(Figure 3B). Each individual protein was then expressed in vitro in a
reticulocyte lysate system using gene-specific PCR product contain-
ing a T7 promoter and incubated with GST-RPL41. The full-length
β- and γ-tubulin as well as N-terminal myosin IIA were readily pulled
down by GST-RPL41. However, no interaction between GST-RPL41
and α-tubulin or C-terminal myosin IIA were detected (Figure 3C). The
interaction between α-tubulin and GST-RPL41 seen in the pull-down
Figure 1. Down-regulation of RPL41 in NIH3T3 cells resulted in malignant transformation. (A) RPL41-specific siRNA effectively knocked
down cellular RPL41 expression. NIH3T3 cells were transfected with two RPL41 siRNA expression constructs or a control construct ex-
pressing a random hairpin siRNA. Western blot analysis was performed with antibodies specific to RPL41 or β-actin. (B) RPL41-depleted
NIH3T3 cells formed foci in liquid culture. No such foci were noted in control cells. (C) RPL41-depleted NIH3T3 cells formed significantly
more colonies than did control cells in soft agar plates. (D) Colonies that exceeded 120 μm in diameter in soft agar plates were counted.
The number of colonies was the average value based on six wells (35 mm). Both cell lines expressing RPL41 siRNA had significantly more
colonies than control cells.
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Figure 2. Deletion and down-regulation of RPL41 in tumors. (A) RPL41 allelic reduction was detected in human tumors. FISH analysis
was performed with an RPL41 BAC clone (red) and a chromosome 12-centromere control probe (green). FISH on normal lymphocytes
showed that RPL41 was located at 12q13 as expected (left). Leukemia cells (CCL246) had two copies of centromere and one copy of
RPL41 (right). FISH results on 22 tumor cell lines were detailed in Table W1. (B) RPL41 expression was significantly decreased in primary
breast cancers. Quantitative real-time RT-PCR was performed with RPL41-specific primers in 12 cases of matched primary breast cancers/
normal pairs. Data represent mean ± SD from three reactions. Clinical information of tumors is detailed in Table W2. Constitutional RPL41
inactivation in case 9 could not be excluded.
Figure 3. Interaction of RPL41 with cytoskeletal components. (A) Cellular tubulin α, β, and γ and myosin IIA were effectively pulled down
by GST-RPL41. Cell lysate was incubated with GST, GST/RPL41, GST/Scrambled RPL41, and GST/Arginine–rich peptide. Western blot
analyses of the GST pull-down products were performed with antibodies to tubulin α, β, and γ and myosin IIA. (B) Cell lysate was in-
cubated with an antibody to RPL41 or rabbit preimmunization serum (control), pulled down by incubation with protein A/G agarose, and
immunoblotted with antibodies to tubulin α, β, and γ, myosin IIA, and RPL41. (C) Individually expressed tubulin β and γ and N-terminal
myosin IIA were effectively pulled down by GST-RPL41. Proteins were expressed in reticulocyte lysate and labeled with 35S methionine.
Myosin IIA was expressed in two overlapping fragments (N-myosin and C-myosin) owing to its large size. (D) RPL41 associated with
polymerized tubulin. A synthetic RPL41 peptide was incubated with purified tubulin in the presence or absence of Taxol. Reactions were
centrifuged, and the supernatant and precipitants were separated in 20% polyacrylamide gel.
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experiment using cellular proteins, therefore, is likely the result of
α-tubulin and β-tubulin heterodimerization. We next studied the
association of RPL41 with the polymerized tubulin by incubating
a synthetic RPL41 peptide with purified tubulin in the presence
or absence of Taxol, a known microtubule polymerization inducer.
Coprecipitation of RPL41 with polymerized tubulin was detected
in the presence of Taxol, consistent with a direct interaction between
RPL41 and microtubule (Figure 3D).
Several microtubule-associated proteins are known to stabilize mi-
crotubule by increasing α-tubulin acetylation. To study whether
RPL41 affects the acetylation of α-tubulin, cells were treated with a
synthetic RPL41, which is self cell-penetrating (unpublished data),
and Western blotted with antibodies to α-tubulin and acetyl-α-tubulin.
As shown in Figure 4A, RPL41 induced a significant increase in
α-tubulin acetylation in both HeLa cells and 293T cells. Immunofluo-
rescence staining on cells overexpressing GFP-RPL41 showed signifi-
cantly more residual acetylated α-tubulin after nocodazole challenge than
those overexpressing a GFP control (Figure 4, B and C ). These results
are suggesting a stabilizing role of RPL41 on microtubule. Pharmaco-
logic intervention of microtubule dynamics is associated with cell cycle
arrest at G2/M. To study whether an exogeneous RPL41 affects cell
cycle, 293T cells were cultured with various concentrations of RPL41
for 16 hours and subjected to a flow cytometry assay. A dose-dependent
G2/M arrest was detected in cells treated with RPL41 (Figure 4D).
Cellular localization of RPL41 was studied by immunofluores-
cence analysis with the anti-RPL41 antibody. In the interphase,
RPL41 is mainly located in nucleoli; diffused signals were also seen
in nuclei and cytoplasm (Figure 5A). The nucleolar localization of
RPL41 was confirmed by its colocalization with the nucleolar marker
B23 (Figure 5A). Colocalization of RPL41 and microtubules was
detected in the pseudopodia of cells (Figure 5B). In mitotic cells,
RPL41 showed a dynamic cellular localization: RPL41 was evenly
distributed in the entire cell in prophase, concentrated on chromo-
somes in metaphase, enriched on chromosomes and spindle midzone
in anaphase, and localized in newly formed nuclei and in midbody in
telophase (Figure 5, C and D). Colocalization of RPL41 with micro-
tubules in midbody was confirmed by immunostaining with anti-
bodies to RPL41 and α-tubulin (Figure 5D). The cellular localization
of RPL41 was verified by a synthetic FITC-conjugated RPL41 peptide,
which showed an identical pattern of localization as described pre-
viously (data not shown).
RPL41 Down-regulation Leads to Abnormal Mitosis
Although no significant morphologic difference was seen between
NIH3T3 cells expressing an RPL41 siRNA and control cells, RPL41-
depleted cells showed sparse cellular microtubules and lack of typical
aster structure in interphase cells (Figure 6A). In mitotic cells, abnor-
mal mitotic spindles, including sparse spindles, lack of centrosome
Figure 4. Acetylation of cellular α-tubulin and G2/M cell cycle arrest induced by RPL41. (A) Significantly increased α-tubulin acetylation
was detected in cells treated with a synthetic RPL41. 293T cells and HeLa cells were incubated with 50 μM synthetic RPL41 or vehicle
control (saline) for 1 hour and Western blotted with antibodies to α-tubulin, acetyl-α-tubulin, and β-actin. (B and C) Cells overexpressing a
GFP-RPL41 showed significantly more residual acetylated α-tubulin after nocodazole challenge than those overexpressing a GFP control.
HeLa cells were transfected with GFP (B) or GFP-RPL41 (C) for 24 hours, treated with 10 μM nocodazole or vehicle control (DMSO) for
20 minutes, immunofluorescence-stained with anti–acetyl-α-tubulin antibody (red), and counterstained with DAPI (blue). (D) Cells treated
with a synthetic RPL41 accumulated at G2/S phase. 293T cells were incubated with 25 to 50 μM RPL41 or vehicle (saline) for 16 hours
and subjected to a flow cytometry assay. Significant increase in G2/M cells was seen in cells treated with RPL41.
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foci, and decreased midzone spindles, were found in RPL41-depleted
NIH3T3 cells (Figure 6B). Immunostaining with anti–γ-tubulin anti-
body on mitotic cells showed an apparent normal pattern of signals in
RPL41-depleted NIH3T3 cells. However, by measuring the distance
between the spindle poles at the end of anaphase, significantly short-
ened mitotic spindles were found in RPL41-depleted cells, with an
average of 9.1 ± 1.89 μm in RPL41-depleted cells compared with
13.6 ± 1.5 μm in control cells (P = 7.4e − 05; n = 20). Similarly,
the two groups of newly segregated chromosomes in telophase stayed
noticeably closer in RPL41-depleted NIH3T3 cells. RPL41-depleted
cells also showed a shorter and twisted midbody, with some con-
taining lagging DNA material (Figure 6C ), probably due to the lack
of enough chromosome separation before cytokinesis. We counted
100 telophase cells with RPL41 depletion; 16 of them had visible
DNA material (DAPI-positive) in midbody; only 2 of 100 control
cells had similar DNA material in midbody. By time-lapse image
analysis under contrast microscopy, RPL41-depleted NIH3T3 cells
showed large membrane bulges at the beginning of cytokinesis; no
such large bulges were seen in control NIH3T3 cells. Cleavage
furrow did occur, although it often regressed, which led to failed cyto-
kinesis (Video W1 and Video W2). A significant increase in poly-
nuclear cells, including some giant cells with up to eight nuclei per
cell, was found in RPL41-depleted cells (Figure 6D). Of 500 cells
counted under contrast microscope, 115 (23%) were polynuclear
cells in RPL41-depleted cells, whereas only 10 (2%) of 500 were
polyploidy cells in control cells.
RPL41 Down-regulation Leads to Centrosome Splitting
Immunofluorescence staining with anti–γ-tubulin antibody on in-
terphase cells showed a different pattern of signals between RPL41-
depleted NIH3T3 cells and control NIH3T3 cells; whereas most
control cells had one signal, most RPL41-depleted cells had two sig-
nals (Figure 7A). Some of the lone signal in control cells showed a
doublet, presumably representing the two centrioles, at higher mag-
nification. No such doublet was seen in either of the two signals in
RPL41-depleted cells. This result suggests a possible premature cen-
trosome split-apart of the two centrioles in RPL41-depleted cells,
although an arrest of cell cycle at G2, when centrosome normally sep-
arates, could not be excluded. A flow cytometry analysis detected
no such G2 arrest; in fact, a slightly but consistently decreased G2
and S cells and slightly increased G1 cells was seen in RPL41-depleted
cells (Table W3). Immunofluorescence staining with antibodies to
γ-tubulin and centrosome protein 170 kDa (Cep170) was then
performed. Cep170 is present in the mother centriole, but not in the
daughter centriole in G1 cells, and in both matured centrosomes at late
G2 [25]. RPL41-depleted cells showed colocalization of γ-tubulin and
Figure 5. Cellular localization of RPL41 on human fibroblasts. Immunofluorescence staining of human fibroblasts was performed with
antibodies to RPL41, nucleolar marker B23, or α-tubulin, and counterstained with DAPI. (A) In interphase cells, RPL41 is located in nu-
cleoli, nuclei, and cytoplasm. Nucleolar localization of RPL41 was verified by costaining with anti-B23. (B) RPL41 was colocalized with
microtubule in the pseudopodia of cells. (C) In mitotic cells, RPL41 was diffused in the entire cell in prophase, concentrated on chromo-
somes in metaphase, enriched in chromosomes and midzone in anaphase, and localized in newly formed nuclei and midbody in telo-
phase. (D) RPL41 was colocalized with α-tubulin in midbody.
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Cep170 in one centrosome and only of γ-tubulin in the other centro-
some (Figure 7B). Considering that most RPL41-depleted cells are in
G1, the observed pattern of γ-tubulin and Cep170 signals in RPL41-
depleted NIH3T3 cells is consistent with a premature centrosome
splitting. To study the nucleation function of the split centrosomes,
a microtubules regrowth assay was performed. Cells were incubated
on ice to depolymerize microtubules, immersed immediately in pre-
warmed complete culture medium (37°C) for repolymerization, fixed
in methanol, and immunofluorescence-stained with antibodies to α-
and γ-tubulin. Whereas control cells showed a nice aster microtubule
structure, no such microtubule regrowth was found in cells with
RPL41 depletion (Figure 7C).
Discussion
Several studies have linked the deregulated ribosome proteins with tu-
mors, although their oncogenic mechanisms remain to be determined.
The involvement of multiple ribosomal proteins in tumors indicates
Figure 6. Abnormal microtubules in NIH3T3 cells with RPL41 down-regulation. (A) RPL41-depleted interphase cells showed sparse cel-
lular microtubules and lack of typical aster structure. NIH3T3 stable cell lines expressing an RPL41-specific siRNA (RPL41 KD) or a con-
trol random siRNA were immunostained with an antibody to α-tubulin and counterstained with DAPI. (B) RPL41-depleted cells showed
abnormal mitotic spindles. Mitotic cells of control and RPL41 KD cells were immunostained with an antibody to α-tubulin and counter-
stained with DAPI. Control cells had spindles focused on centrosomes, seen as prominent bright foci (arrowheads). These foci were
undetectable in RPL41-depleted cells. RPL41-depleted cells also showed lack of midzone spindles in anaphase. (C) Lagged DNA materials
were commonly seen in the midbodies in RPL41-depleted cells. (D) Increased polynuclear cells were seen in RPL41-depleted NIH3T3 cells.
Approximately 80% decrease in cellular RPL41 in cells expressing a RPL41-specific siRNA was verified by Western blot analysis.
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that they may use a common oncogenic pathway. Deregulation of
translation is an obvious possibility. However, it is puzzling that some
ribosomal proteins involved in tumors are downregulated, whereas the
cellular translation is presumably increased in tumors. Several studies
provided evidence that many ribosomal proteins have extraribosomal
functions unrelated to cellular translation. Our studies showed that
RPL41 is a microtubule-associated protein, and cells with defective
RPL41 had abnormal mitosis with frequent cytokinesis failure and in-
creased polynuclear cells. Abnormal mitosis could lead to genome in-
stability and facilitate malignant transformation [26]. Polynuclear cells
are also more sensitive to carcinogens [27]. It is likely that the abnor-
mal mitosis and polynuclear cells in RPL41 defective cells contribute
to malignant transformation. An interesting question is whether other
ribosomal protein defects use a similar hypothetical oncogenic path-
way. Microtubule-associated proteins are typically basic proteins that
interact with the acid region of tubulin [28]; most ribosomal proteins
are basic proteins [29] and therefore potential microtubule-binding
proteins. A proteomic study on isolated midbodies, a microtubule-
based structure important for cytokinesis, showed that 13% of 577
proteins are ribosomal proteins [30]. The possibility that other ribo-
somal proteins may play roles in mitosis, therefore, is worth further
study. Interestingly, RPL41 was not one of the midbody-associated
proteins in the proteomic study of midbody, although our results clearly
showed a midbody localization. RPL41 is unique in that 17 of 25 amino
acids are arginines and lysines, which are cleaved by trypsin digestion
before peptide mass fingerprinting. Small fragments of RPL41 are likely
beyond the resolution of mass spectrum.
In addition to failed cytokinesis, we frequently observed lagged
chromatids inside cleavage furrow in RPL41-depleted cells, which
are probably caused by the shortened mitotic spindles and the lack
of enough chromosome separation before cytokinesis. A potential
detrimental effect of this abnormality is that the force of contractile
ring could fracture these lagged DNA. A loss of DNA fragments en-
coding tumor suppressors will contribute to malignant transfor-
mation. For example, chromosome 1, the longest chromosome of the
cell that may be more likely to be “stuck” in midbody, is suspected to
harbor multiple tumor suppressors [31].
Our results showed that cells with RPL41 down-regulation had pre-
mature centrosome splitting. Centrosome is an organelle that serves as
the main microtubule-organizing center. Centrosome abnormalities
have been detected in early tumors [32] and in human cells infected
with tumor-causing virus [33]. Centrosome at G1 is consisted of two
centrioles held together by a dynamic linker. A procentriole is formed
adjacent to each of the two parental centrioles during S and G2, and the
two matured centrosomes are separated just before the onset of mitosis
to form the poles of the bipolar spindle apparatus. Centrosome cohe-
sion is regulated by a balance of centrosome-associated kinase and phos-
phatase activity; both overexpression of centrosome-associated kinases
or inhibition of phosphatases induced centrosome splitting [34]. It is
proposed that the phosphorylation status of the docking site for the
centriole linker regulates the centrosome cohesion [35]. Microtubule-
destabilizing agents are known to induce centrosome splitting likely
through an imbalance of centrosome-associated kinases and phos-
phatases caused by the defective microtubule flux. The mechanism of
Figure 7. Centrosome abnormality in NIH3T3 cells with RPL41 down-regulation. (A) Majority of RPL41-depleted cells had premature
centrosome splitting. Interphase cells of NIH3T3 cells expressing an RPL41-specific siRNA (RPL41 KD) or a control random siRNA were
immunostained with an antibody to γ-tubulin and counterstained with DAPI. Control cells had one signal with some consisting of a
doublet (insert). Most RPL41-depleted cells had two signals (arrowhead) without doublet (insert). (B) Only one of the split centrioles
was-positive to Cep170 in RPL41-depleted cells. Control and RPL41 KD cells were immunostained with antibodies to γ-tubulin and
Cep170 (red) and counterstained with DAPI. (C) Defective microtubule regrowth in cells with RPL41 down-regulation. RPL41 KD cells
and control cells were subjected to a microtubule regrowth assay followed by immunostaining with antibodies to α-tubulin and γ-tubulin.
Typical microtubule asters were seen in control cells but not in RPL41-depleted cells with split centrosomes.
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centrosome splitting in RPL41-depleted cells is unclear. RPL41 is a
microtubule-associated protein that stabilizes the microtubule. It is pos-
sible that the lack of RPL41 in cells renders microtubule unstable and
therefore premature centrosome splitting.
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Online Supplemental Material
Evaluation of Specificity of RPL41 Antibody
The specificity of the antibody to RPL41 was evaluated in the fol-
lowing studies: (1) Immunofluorescence staining of human fibro-
blasts with anti-RPL41 antibody showed a predominant nuclei and
nucleoli localization with weak cytoplasmic staining, consistent with
the results obtained from a penetrating FITC-conjugated synthetic
RPL41 and the expression of a GFP/RPL41 construct (Figure 5, A
and B; manuscript submitted); (2) Western blot analysis of human
cell lysis showed a single band that comigrated with the synthetic
RPL41 (Figure W1); RPL41 needed to be transferred onto mem-
branes in a reversed electronic field, that is, from anode to cathode,
consistent with the extremely basic nature of RPL41; and (3) West-
ern blot analysis of NIH3T3 cells expressing an RPL41 siRNA oligo
showed that the RPL41 was specifically knocked down (Figure 1A).
Figure W1. Specificity valuation of the custom anti-RPL41 antibody.
Protein lysates from normal human fibroblasts and a synthetic RPL41
were transferredontopolyvinylidene fluoridemembrane in a reversed
electronic field and immunoblotted with the anti-RPL41 antibody.
Table W1. Twenty-two ATCC Cancer Cell Lines Used for RPL41 Sequencing and FISH Analysis.
Tumor Type ATCC Case No. (Designation) RPL41 Allelic Reduction
Breast cancer CRL2340 (HCC2157) No
CRL2331 (HCC1599) Yes
CRL1500 (ZR-75-1) Yes
CRL1902 (UACC-893) Yes
CRL2343 (HCC2218) Yes
HTB123 (DU4475) No
HTB20 (BT-474) Yes
Prostate cancer CRL5813 (NCI-H660) Yes
CRL2505 (22Rv1) No
CRL1740 (LNCaP clone FGC) No
CRL1435 (PC-3) Yes
HTB81 (DU 145) No
Lung cancer CRL5803 (NCI-H1299) Yes
CRL5800 (NCI-H23) Yes
HTB174 (NCI-H441) Yes
HTB184 (NCI-H510A) Yes
Leukemia CCL240 (HL-60) No
CCL243 (K-562) No
CCL246 (KG-1) Yes
CRL2725 (Kasumi-3) No
Colon cancer CL187 (LS 180) No
Melanoma HTB72 (SK-MEL-28) Yes
FISH results are detailed in column 3.
Video W1. Normal mitosis in control NIH3T3 cells. Images were
taken with an Olympus IX71 microscope/Olympus DP71 camera
(Olympus, Hamburg, Germany) every 2 minutes.
Video W2. Abnormal mitosis in RPL41-depleted NIH3T3 cells.
One of the two dividing cells (the top cell) showed failed cytokine-
sis. At the start of the video, the top cell appeared to be in early
anaphase. Membrane bulges could be seen. Cleavage furrow ap-
peared before regression and a dinuclear cell was formed.
Table W3. Flow Cytometry Analysis of RPL41-Depleted and Control NIH3T3 Cells.
Cases G1 S G2
1 2 3 4 1 2 3 4 1 2 3 4
Control 72.6 67.1 73.0 67.9 8.4 9.2 8.0 9.8 18.9 23.7 19.0 22.3
RPL41 siRNA no. 1 81.9 80.4 81.7 80.5 4.7 4.9 4.8 4.4 13.4 14.7 13.5 15.1
RPL41 siRNA no. 2 81.2 81.9 81.1 80.9 5.1 5.1 4.9 5.0 13.4 13.0 14.0 14.0
Table W2. Clinical Informationof 12Breast CancersUsed forQuantitativeRPL41ExpressionAnalysis.
Case No. Classification DCIS/LCIS Status Size (cm) Grade Node Invasion ER/PR Status
1 IDC +/− 1.8 2 − +/−
2 IDC/ILC +/+ 2.2 3 + +/−
3 IDC +/+ 3.5 2 − −/+
4 IDC +/− 3 3 + −/+
5 IDC +/+ 3 2 + +/+
6 IDC −/− 2.5 2 + +/+
7 IDC +/− 5 2 ++ −/−
8 IDC +/− 3 2 ++ +/+
9 IDC +/− >7 3 + +/+
10 IDC +/− 4 3 − −/−
11 IDC +/− 2.5 2 + −/−
12 IDC/ILC +/+ 3.3 2 + +/+
DCIS indicates ductal carcinoma in situ; ER, estrogen receptor; IDC, invasive ductal carcinoma;
ILC, invasive lobular carcinoma; LCIS, lobular carcinoma in situ; PR, progesterone receptor.
